Calendario de promoción Lumos Pharma, Inc.
Horario avanzado
gráfico sencillo
Acerca de la empresa
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
| Выручка |
0.000936 |
| EBITDA |
-0.0429 |
| Число акций ао |
0.00815 млрд |
| P/S |
3.08 |
| P/BV |
0.0365 |
| EV/EBITDA |
2.01 |
| Цена ао |
2.88 |
| ISIN |
US55028X1090 |
| Сайт |
https://lumos-pharma.com
|
| Валюта |
usd |
| IPO date |
2011-11-11 |
| Sector |
Health Care |
| Industry |
Biotechnology |
| Валюта отчета |
usd |
| Cambio de precio por día: |
-0.545% (3.67) |
| Cambio de precio por semana.: |
-4.95% (3.84) |
| Cambio de precio por mes: |
-7.59% (3.95) |
| Cambio de precio en 3 meses.: |
+65.16% (2.21) |
| Cambio de precio en seis meses: |
+37.74% (2.65) |
| Cambio de precio por año: |
-10.76% (4.09) |
| Cambio de precio en 3 años.: |
-65.89% (10.7) |
| Cambio de precio en 5 años.: |
+128.13% (1.6) |
| Cambio de precio desde principios de año.: |
+25.86% (2.9) |
|
|
Subestimación
| Nombre |
Significado |
Calificación |
| P/S |
12.07 |
1 |
| P/BV |
0.9068 |
9 |
| P/E |
0 |
0 |
| EV/EBITDA |
0.102 |
10 |
| Total: |
|
5 |
|
Eficiencia
| Nombre |
Significado |
Calificación |
| ROA, % |
-83.75 |
0 |
| ROE, % |
-124.64 |
0 |
| Total: |
|
0 |
|
|
|
Dividendos
| Nombre |
Significado |
Calificación |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| Total: |
|
0.0557 |
|
Deber
| Nombre |
Significado |
Calificación |
| Debt/EBITDA |
-0.1801 |
10 |
| Total: |
|
9.8 |
|
Impulso de crecimiento
| Nombre |
Significado |
Calificación |
| Rentabilidad Revenue, % |
119.12 |
10 |
| Rentabilidad Ebitda, % |
-14.76 |
0 |
| Rentabilidad EPS, % |
-87.34 |
0 |
| Total: |
|
2.2 |
|
| Supervisor |
Título profesional |
Pago |
año de nacimiento |
| Mr. Richard J. Hawkins |
Founder, CEO & Chairman |
854.35k |
1949 (75 años) |
| Dr. John C. McKew Ph.D. |
Chief Scientific Officer & President |
860.38k |
1964 (60 años) |
| Ms. Lori D. Lawley CPA |
CFO & Principal Accounting Officer |
538.23k |
1984 (40 años) |
| Mr. Bradley J. Powers J.D. |
Chief Compliance Officer & General Counsel |
677.08k |
1979 (45 años) |
| Mr. Aaron Schuchart B.B.A., CPA, M.B.A. |
Chief Business Officer |
N/A |
1966 (58 años) |
| Dr. Pisit Pitukcheewanont FAAP, M.D. |
Chief Medical Officer |
N/A |
|
| Mr. Eddie L. Varnado M.B.A. |
Corporate Controller |
N/A |
|
| Ms. Lisa Wells Miller |
Senior Director of Investor Relations |
N/A |
|
| Ms. Alpa Parikh |
Senior Vice President of CMC & Supply Management |
|
|
